Physician profile
Mir A Zulqarnain
NPI 1780145458
$160,983.63
in general payments reported to CMS, 2019-2025
7 companies · $160K in 2025
The $160K reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $178 · 2023: $248 · 2024: $337 · 2025: $160K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $160K · Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $160,000.00 |
| Food and Beverage | $805.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $160,000.00 | 2025 | |
| Abbvie INC. | $361.46 | 2023-2025 | Rinvoq |
| Gilead Sciences, INC. | $237.69 | 2022-2024 | Epclusa |
| Intercept Pharmaceuticals, INC. | $124.99 | 2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $104.39 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $101.36 | 2025 | Dupixent |
| Boston Scientific Corporation | $53.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mir Zulqarnain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.